PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27055578-4	2016	Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile.	Chlorambucil	144-156	keratin 20	Homo sapiens	83-87	
26951237-4	2016	For the frailest patients, CD20 monoclonal antibodies with or without chlorambucil have proven to be efficacious.	Chlorambucil	70-82	keratin 20	Homo sapiens	27-31	
27055578-4	2016	Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile.	Chlorambucil	302-314	keratin 20	Homo sapiens	83-87	
27055578-4	2016	Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile.	Chlorambucil	302-314	keratin 20	Homo sapiens	83-87	
26489498-4	2015	Rituximab and the newest anti-CD20 antibody obinutuzumab in combination with chlorambucil, as compared with chlorambucil alone, prolonged overall survival in previously untreated patients with significant comorbidities, and the combination of anti-CD20 antibody with chlorambucil has become the standard regimen in this group of patients.	Chlorambucil	77-89	keratin 20	Homo sapiens	248-252	
25479582-3	2015	In a recent randomized Phase III study of patients with newly diagnosed CLL and coexisting conditions, obinutuzumab, a humanized anti-CD20 glycoengineered type 2 antibody, used in combination with chlorambucil, demonstrated significant improvement in progression-free survival and several other outcome parameters, in comparison to rituximab plus chlorambucil.	Chlorambucil	347-359	keratin 20	Homo sapiens	134-138	
24098639-0	2013	New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles.	Chlorambucil	82-94	keratin 20	Homo sapiens	126-130	
24098639-3	2013	In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody.	Chlorambucil	119-131	keratin 20	Homo sapiens	197-201	
24098639-8	2013	In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab.	Chlorambucil	107-119	keratin 20	Homo sapiens	53-57	
24098639-9	2013	These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders.	Chlorambucil	101-113	keratin 20	Homo sapiens	50-54